Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Accounts Payables (2019 - 2025)

Pulmonx (LUNG) has disclosed Accounts Payables for 7 consecutive years, with $6.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 40.3% to $6.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.4 million, a 40.3% increase, with the full-year FY2024 number at $3.8 million, up 155.64% from a year prior.
  • Accounts Payables was $6.4 million for Q3 2025 at Pulmonx, down from $6.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.6 million in Q2 2025 to a low of $1.5 million in Q4 2023.
  • A 5-year average of $3.2 million and a median of $2.9 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: tumbled 40.28% in 2022, then soared 155.64% in 2024.
  • Pulmonx's Accounts Payables stood at $1.6 million in 2021, then rose by 11.13% to $1.8 million in 2022, then decreased by 14.85% to $1.5 million in 2023, then skyrocketed by 155.64% to $3.8 million in 2024, then surged by 67.76% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Accounts Payables are $6.4 million (Q3 2025), $6.6 million (Q2 2025), and $4.3 million (Q1 2025).